DRG Market Assessment reports

Clarivate Epidemiology’s coverage of non-small-cell lung cancer (NSCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of non-small-cell lung cancer (NSCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of non-small-cell lung cancer (NSCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Prostate cancer is the second-most-prevalent cancer in men, significantly impacting male mortality rates. Hormonal therapy is a cornerstone of drug treatment for all stages of prostate cancer…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key non-small-cell lung cancer patient populations, covering 171…

Clarivate Epidemiology’s coverage of non-small-cell lung cancer (NSCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of NSCLC comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and diagnosed…

Clarivate Epidemiology’s coverage of non-small-cell lung cancer (NSCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Several therapies from a range of drug classes are available to address the symptoms of narcolepsy; these symptoms include excessive daytime sleepiness (EDS) and cataplexy. Despite the availability…

Over the past two decades, in response to mounting failures, clinical trials of disease-modifying therapies (DMTs) in Alzheimer’s disease (AD) have moved earlier in the disease spectrum to…

Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s donanemab (Kisunla) are modestly effective in reducing cognitive and functional decline, require frequent IV infusions, and carry ARIA-…

Clarivate Epidemiology’s coverage of SCCHN comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed events of SCCHN for each country, as…